Spermiogram Assessment in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis
- First Posted Date
- 2015-05-01
- Last Posted Date
- 2019-03-04
- Lead Sponsor
- Knight Therapeutics (USA) Inc
- Target Recruit Count
- 55
- Registration Number
- NCT02431429
- Locations
- 🇧🇴
Funderama, Santa Cruz, Bolivia
Dedicated QT Study in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis
- First Posted Date
- 2015-04-29
- Last Posted Date
- 2020-09-04
- Lead Sponsor
- Knight Therapeutics (USA) Inc
- Target Recruit Count
- 42
- Registration Number
- NCT02429518
- Locations
- 🇧🇴
Funderma, Santa Cruz, Bolivia
Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry
- First Posted Date
- 2015-04-29
- Last Posted Date
- 2020-08-28
- Lead Sponsor
- Knight Therapeutics (USA) Inc
- Registration Number
- NCT02429505
- Locations
- 🇺🇸
Fast-Track Drugs and Biologics, LLC, Poolesville, Maryland, United States
Treatment of Leishmaniasis With Impavido® (Miltefosine): Pregnancy Registry
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Knight Therapeutics (USA) Inc
- Target Recruit Count
- 2
- Registration Number
- NCT02427308
- Locations
- 🇺🇸
Fast Track, North Potomac, Maryland, United States
Miltefosine to Treat Mucocutaneous Leishmaniasis
Phase 2
Completed
- Conditions
- Cutaneous LeishmaniasisMucosal Leishmaniasis
- Interventions
- First Posted Date
- 2010-01-18
- Last Posted Date
- 2020-09-30
- Lead Sponsor
- Knight Therapeutics (USA) Inc
- Target Recruit Count
- 4
- Registration Number
- NCT01050907
- Locations
- 🇺🇸
For this treatment IND, each Physician entered patients at his/her own facility. Below data is for protocol central contact:, Bethesda, Maryland, United States
🇺🇸NIH, Bethesda, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath